Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series
The initial RNAi Roundtable schedule will be as follows:
- Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis
Monday, September 16, 1:00 pm ET
- Givosiran, in Development for the Treatment of Acute Hepatic Porphyria
Monday, October 7, 9:30 am ET
- Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
Thursday, October 10, 11:30 am ET
Please visit the Capella section of our website for the latest information regarding webcast schedules.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of diseases with high unmet need. Alnylam’s first commercial RNAi therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU,
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)